Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the ...

ADAR1 Capital Management, 13.3% shareholder of Keros Therapeutics (NASDAQ:KROS), issued an open letter to the company related ...

ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Keros Therapeutics, Inc. (KROS) shares soared 5.1% in the last trading session to close at $11.41. The move was backed by solid volume with far more shares changing hands than in a normal session.

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Keros Therapeutics, Inc. (NASDAQ:KROS) suffered a major setback back in December 2024 when it announced that it had to halt its TROPOS phase 2 trial. This trial was evaluating the use of its drug ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...